Ignite Creation Date:
2024-05-06 @ 12:34 PM
Last Modification Date:
2024-10-26 @ 1:01 PM
Study NCT ID:
NCT03797326
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-10-31
First Post:
2019-01-07
Brief Title:
Efficacy and Safety of Pembrolizumab MK-3475 Plus Lenvatinib E7080MK-7902 in Previously Treated Participants With Select Solid Tumors MK-7902-005E7080-G000-224LEAP-005
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-02-12
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12-20
Completion Date Type:
ESTIMATED
First Submit Date:
2019-01-07
First Submit QC Date:
January 7 2019
Study First Post Date:
2019-01-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-15
Last Update Post Date:
2023-10-31
Last Update Post Date Type:
ACTUAL